Shiga Toxins: Pathogenicity and Therapeutic Applications
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 3705
Special Issue Editor
2. Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Daejeon 34141, Republic of Korea
Interests: Bacterial toxins; Shiga toxin-producing E.coli; Shiga toxins; hemolytic uremic syndrome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Shigellosis caused by Shiga toxin (Stx)-producing Shigella dysenteriae serotype 1 or Stx-producing Escherichia coli (STEC) continues to be a major public health threat and is a particular concern because of the potential to develop life-threatening extra-intestinal complications, such as acute renal failure (hemolytic uremic syndrome; HUS), and CNS complications, such as seizures, paralysis, and death. Once Shiga toxins (Stxs) are internalized following the toxin-receptor binding on host cellular surface, they are trafficked into the Golgi apparatus and to the ER in a retrograde manner to enter the host cell cytosol, leading to various host cellular responses, including protein synthesis inhibition, apoptosis through ER stress, autophagy, and inflammation. Distinct investigations on host cell signaling responses activated by Stxs as multifunctional proteins are necessary to identify novel targets for intervention in pathogenesis. Moreover, many studies present compelling and strong evidence regarding therapeutic applications to target particular diseases, such as tumors, by engineering the toxins.
At the molecular, cellular or clinical level, an improved understanding of the pathogenesis of the diseases’ bacillary dysentery and hemorrhagic colitis, and the subsequent development of extra-intestinal/extrarenal complications caused by STEC, will be necessary to develop effective protective and interventional therapies to treat patients infected with the organism.
This Special Issue of Toxins will focus on recent advances to consider unexplored mechanisms of STEC-mediated pathogenesis, current therapeutic applications or STEC genetics contributing to pathogenicity.
Prof. Dr. Moo-Seung Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Shiga toxins
- Shiga toxin-producing Shigella species
- Shiga toxin-producing Escherichia coli
- hemolytic uremic syndrome
- Shiga toxins-mediated pathogenesis
- cancer therapeutics
- toxin engineering
